Cancer Research Targets Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v68,p9566)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nahta, R.
Right arrow Articles by Esteva, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nahta, R.
Right arrow Articles by Esteva, F. J.
[Cancer Research 65, 11118-11128, December 1, 2005]
© 2005 American Association for Cancer Research

Experimental Therapeutics, Molecular Targets, and Chemical Biology

Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer Cells

Rita Nahta1, Linda X.H. Yuan1, Bing Zhang1, Ryuji Kobayashi2 and Francisco J. Esteva1,3,4

Departments of 1 Breast Medical Oncology, 2 Molecular Pathology, and 3 Molecular and Cellular Oncology, The University of Texas M.D. Anderson Cancer Center and 4 The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas

Requests for reprints: Rita Nahta or Francisco J. Esteva, Department of Breast Medical Oncology, Unit 1354, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-4009. Phone: 713-792-2817; Fax: 713-563-0739; E-mail: rnahta{at}mdanderson.org or festeva{at}mdanderson.org.

The majority of breast cancer patients who achieve an initial therapeutic response to the human epidermal growth factor receptor 2 (HER-2)–targeted antibody trastuzumab will show disease progression within 1 year. We previously reported the characterization of SKBR3-derived trastuzumab-resistant pools. In the current study, we show that HER-2 interacts with insulin-like growth factor-I receptor (IGF-IR) uniquely in these resistant cells and not in the parental trastuzumab-sensitive cells. The occurrence of cross talk between IGF-IR and HER-2 exclusively in resistant cells is evidenced by the IGF-I stimulation resulting in increased phosphorylation of HER-2 in resistant cells, but not in parental cells, and by the inhibition of IGF-IR tyrosine kinase activity leading to decreased HER-2 phosphorylation only in resistant cells. In addition, inhibition of IGF-IR tyrosine kinase activity by I-OMe-AG538 increased sensitivity of resistant cells to trastuzumab. HER-2/IGF-IR interaction was disrupted on exposure of resistant cells to the anti–IGF-IR antibody {alpha}-IR3 and, to a lesser extent, when exposed to the anti-HER-2 antibody pertuzumab. Heterodimer disruption by {alpha}-IR3 dramatically restored sensitivity to trastuzumab and resistant cells showed a slightly increased sensitivity to pertuzumab versus parental cells. Neither {alpha}-IR3 nor pertuzumab decreased HER-2 phosphorylation, suggesting that additional sources of phosphorylation other than IGF-IR exist when HER-2 and IGF-IR are not physically bound. Our data support a unique interaction between HER-2 and IGF-IR in trastuzumab-resistant cells such that cross talk occurs between IGF-IR and HER-2. These data suggest that the IGF-IR/HER-2 heterodimer contributes to trastuzumab resistance and justify the need for further studies examining this complex as a potential therapeutic target in breast cancers that have progressed while on trastuzumab.




This article has been cited by other articles:


Home page
 Ann OncolHome page
K. L. Blackwell, M. D. Pegram, E. Tan-Chiu, L. S. Schwartzberg, M. C. Arbushites, J. D. Maltzman, J. K. Forster, S. D. Rubin, S. H. Stein, and H. J. Burstein
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens
Ann. Onc., June 1, 2009; 20(6): 1026 - 1031.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. Dokmanovic, D. S. Hirsch, Y. Shen, and W. J. Wu
Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer
Mol. Cancer Ther., June 1, 2009; 8(6): 1557 - 1569.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Gori, A. Sidoni, M. Colozza, I. Ferri, M. G. Mameli, D. Fenocchio, L. Stocchi, J. Foglietta, V. Ludovini, E. Minenza, et al.
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab
Ann. Onc., April 1, 2009; 20(4): 648 - 654.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. Kaulfuss, P. Burfeind, J. Gaedcke, and J.-G. Scharf
Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis
Mol. Cancer Ther., April 1, 2009; 8(4): 821 - 833.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. S. Ross, E. A. Slodkowska, W. F. Symmans, L. Pusztai, P. M. Ravdin, and G. N. Hortobagyi
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
Oncologist, April 1, 2009; 14(4): 320 - 368.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. K. Saxena, L. Taliaferro-Smith, B. B. Knight, D. Merlin, F. A. Anania, R. M. O'Regan, and D. Sharma
Bidirectional Crosstalk between Leptin and Insulin-like Growth Factor-I Signaling Promotes Invasion and Migration of Breast Cancer Cells via Transactivation of Epidermal Growth Factor Receptor
Cancer Res., December 1, 2008; 68(23): 9712 - 9722.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
G. D. Lewis Phillips, G. Li, D. L. Dugger, L. M. Crocker, K. L. Parsons, E. Mai, W. A. Blattler, J. M. Lambert, R. V.J. Chari, R. J. Lutz, et al.
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
Cancer Res., November 15, 2008; 68(22): 9280 - 9290.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Correction: IGF-IR/HER-2 Contributes to Trastuzumab Resistance
Cancer Res., November 15, 2008; 68(22): 9566 - 9566.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. Esparis-Ogando, A. Ocana, R. Rodriguez-Barrueco, L. Ferreira, J. Borges, and A. Pandiella
Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells
Ann. Onc., November 1, 2008; 19(11): 1860 - 1869.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. L. Chen, W. Xia, and N. L. Spector
Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors
Clin. Cancer Res., November 1, 2008; 14(21): 6730 - 6734.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Buck, A. Eyzaguirre, M. Rosenfeld-Franklin, S. Thomson, M. Mulvihill, S. Barr, E. Brown, M. O'Connor, Y. Yao, J. Pachter, et al.
Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors
Cancer Res., October 15, 2008; 68(20): 8322 - 8332.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. Rodon, V. DeSantos, R. J. Ferry Jr., and R. Kurzrock
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: Lessons from the first clinical trials
Mol. Cancer Ther., September 1, 2008; 7(9): 2575 - 2588.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Haluska, J. M. Carboni, C. TenEyck, R. M. Attar, X. Hou, C. Yu, M. Sagar, T. W. Wong, M. M. Gottardis, and C. Erlichman
HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924
Mol. Cancer Ther., September 1, 2008; 7(9): 2589 - 2598.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. L. Wilsbacher, Q. Zhang, L. A. Tucker, R. D. Hubbard, G. S. Sheppard, N. Y. Bamaung, S. D. Fidanze, G. T. Wang, X. Hu, S. K. Davidsen, et al.
Insulin-like Growth Factor-1 Receptor and ErbB Kinase Inhibitor Combinations Block Proliferation and Induce Apoptosis through Cyclin D1 Reduction and Bax Activation
J. Biol. Chem., August 29, 2008; 283(35): 23721 - 23730.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
D. L. Rowe, T. Ozbay, L. M. Bender, and R. Nahta
Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer
Mol. Cancer Ther., July 1, 2008; 7(7): 1900 - 1908.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. Piao, Y. Wang, Y. Adachi, H. Yamamoto, R. Li, A. Imsumran, H. Li, T. Maehata, M. Ii, Y. Arimura, et al.
Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas
Mol. Cancer Ther., June 1, 2008; 7(6): 1483 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. J. Burstein, A. M. Storniolo, S. Franco, J. Forster, S. Stein, S. Rubin, V. M. Salazar, and K. L. Blackwell
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer
Ann. Onc., June 1, 2008; 19(6): 1068 - 1074.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
T. Ozbay and R. Nahta
A Novel Unidirectional Cross-Talk from the Insulin-Like Growth Factor-I Receptor to Leptin Receptor in Human Breast Cancer Cells
Mol. Cancer Res., June 1, 2008; 6(6): 1052 - 1058.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. N. Contessa, M. S. Bhojani, H. H. Freeze, A. Rehemtulla, and T. S. Lawrence
Inhibition of N-Linked Glycosylation Disrupts Receptor Tyrosine Kinase Signaling in Tumor Cells
Cancer Res., May 15, 2008; 68(10): 3803 - 3809.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. C. Portera, J. M. Walshe, D. R. Rosing, N. Denduluri, A. W. Berman, U. Vatas, M. Velarde, C. K. Chow, S. M. Steinberg, D. Nguyen, et al.
Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer
Clin. Cancer Res., May 1, 2008; 14(9): 2710 - 2716.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. L. Shattuck, J. K. Miller, K. L. Carraway III, and C. Sweeney
Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells
Cancer Res., March 1, 2008; 68(5): 1471 - 1477.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. K. Chakraborty, K. Liang, and M. P. DiGiovanna
Co-Targeting Insulin-Like Growth Factor I Receptor and HER2: Dramatic Effects of HER2 Inhibitors on Nonoverexpressing Breast Cancer
Cancer Res., March 1, 2008; 68(5): 1538 - 1545.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Massarweh, C. K. Osborne, C. J. Creighton, L. Qin, A. Tsimelzon, S. Huang, H. Weiss, M. Rimawi, and R. Schiff
Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function
Cancer Res., February 1, 2008; 68(3): 826 - 833.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C.-H. Lu, S. L. Wyszomierski, L.-M. Tseng, M.-H. Sun, K.-H. Lan, C. L. Neal, G. B. Mills, G. N. Hortobagyi, F. J. Esteva, and D. Yu
Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency
Clin. Cancer Res., October 1, 2007; 13(19): 5883 - 5888.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. J. Gills, J. LoPiccolo, J. Tsurutani, R. H. Shoemaker, C. J.M. Best, M. S. Abu-Asab, J. Borojerdi, N. A. Warfel, E. R. Gardner, M. Danish, et al.
Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo
Clin. Cancer Res., September 1, 2007; 13(17): 5183 - 5194.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Kumar
ErbB-Dependent Signaling as a Determinant of Trastuzumab Resistance
Clin. Cancer Res., August 15, 2007; 13(16): 4657 - 4659.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. Ritter, M. Perez-Torres, C. Rinehart, M. Guix, T. Dugger, J. A. Engelman, and C. L. Arteaga
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
Clin. Cancer Res., August 15, 2007; 13(16): 4909 - 4919.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. X.-D. Song, Z. Zhang, Y. Chen, Y. Bao, and R. J. Santen
Estrogen Signaling via a Linear Pathway Involving Insulin-Like Growth Factor I Receptor, Matrix Metalloproteinases, and Epidermal Growth Factor Receptor to Activate Mitogen-Activated Protein Kinase in MCF-7 Breast Cancer Cells
Endocrinology, August 1, 2007; 148(8): 4091 - 4101.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G Valabrega, F Montemurro, and M Aglietta
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
Ann. Onc., June 1, 2007; 18(6): 977 - 984.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
J. T. Garrett, S. Rawale, S. D. Allen, G. Phillips, G. Forni, J. C. Morris, and P. T. P. Kaumaya
Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu
J. Immunol., June 1, 2007; 178(11): 7120 - 7131.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
D. L. Shattuck, J. K. Miller, M. Laederich, M. Funes, H. Petersen, K. L. Carraway III, and C. Sweeney
LRIG1 Is a Novel Negative Regulator of the Met Receptor and Opposes Met and Her2 Synergy
Mol. Cell. Biol., March 1, 2007; 27(5): 1934 - 1946.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. L. Arteaga
Will Single-Time Tumor Profiling and a "Guilt by Association" Approach Allow Us to Outsmart HER2-Positive Breast Cancer?
Clin. Cancer Res., February 15, 2007; 13(4): 1071 - 1073.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. N. Harris, F. You, S. J. Schnitt, A. Witkiewicz, X. Lu, D. Sgroi, P. D. Ryan, S. E. Come, H. J. Burstein, B.-A. Lesnikoski, et al.
Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer
Clin. Cancer Res., February 15, 2007; 13(4): 1198 - 1207.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Nahta, L. X.H. Yuan, Y. Du, and F. J. Esteva
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling
Mol. Cancer Ther., February 1, 2007; 6(2): 667 - 674.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. C. Chang
HER2 Inhibition: From Discovery to Clinical Practice
Clin. Cancer Res., January 1, 2007; 13(1): 1 - 3.
[Full Text] [PDF]

Home page
 EndocrinologyHome page
J. M. Fleming, G. Desury, T. A. Polanco, and W. S. Cohick
Insulin Growth Factor-I and Epidermal Growth Factor Receptors Recruit Distinct Upstream Signaling Molecules to Enhance AKT Activation in Mammary Epithelial Cells
Endocrinology, December 1, 2006; 147(12): 6027 - 6035.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J Riedemann and V M Macaulay
IGF1R signalling and its inhibition
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S33 - S43.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
H. E Jones, J. M W Gee, I. R Hutcheson, J. M Knowlden, D. Barrow, and R. I Nicholson
Growth factor receptor interplay and resistance in cancer
Endocr. Relat. Cancer, December 1, 2006; 13(Supplement_1): S45 - S51.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. Meric-Bernstam and M.-C. Hung
Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.
Clin. Cancer Res., November 1, 2006; 12(21): 6326 - 6330.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. E. Johnson and P. A. Janne
Rationale for a Phase II Trial of Pertuzumab, a HER-2 Dimerization Inhibitor, in Patients with Non-Small Cell Lung Cancer.
Clin. Cancer Res., July 15, 2006; 12(14): 4436s - 4440s.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
W. Xia, S. Bacus, P. Hegde, I. Husain, J. Strum, L. Liu, G. Paulazzo, L. Lyass, P. Trusk, J. Hill, et al.
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
PNAS, May 16, 2006; 103(20): 7795 - 7800.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.